Subhashis Banerjee Sells 7,037 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Subhashis Banerjee sold 7,037 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total value of $63,403.37. Following the completion of the transaction, the insider owned 144,963 shares in the company, valued at $1,306,116.63. This represents a 4.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $7.84 on Thursday. The stock’s 50 day moving average price is $8.36 and its 200 day moving average price is $5.67. Artiva Biotherapeutics, Inc. has a 52 week low of $1.47 and a 52 week high of $14.53. The company has a market capitalization of $193.80 million, a P/E ratio of -2.21 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, sell-side analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of large investors have recently added to or reduced their stakes in ARTV. Prelude Capital Management LLC bought a new stake in Artiva Biotherapeutics during the third quarter worth approximately $41,000. Bank of America Corp DE boosted its position in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares during the period. Bridgeway Capital Management LLC bought a new stake in Artiva Biotherapeutics during the second quarter worth approximately $53,000. Qube Research & Technologies Ltd bought a new stake in Artiva Biotherapeutics during the second quarter worth approximately $58,000. Finally, Jane Street Group LLC bought a new stake in Artiva Biotherapeutics during the second quarter worth approximately $67,000.

Key Stories Impacting Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva announced multiple AlloNK® data presentations for the upcoming EULAR 2026 Congress, including a late-breaking oral presentation highlighting clinical efficacy comparable to autologous CAR T-cell therapy in rheumatologic diseases. Article Title
• Positive Sentiment: The company appointed veteran biotech executive Diego Miralles, M.D., as President and Head of Research and Development, which could strengthen leadership and development execution. Article Title
• Neutral Sentiment: Artiva disclosed several insider sales by CEO Fred Aslan, COO Jennifer Bush, SVP Heather Raymon, and insider Christopher Horan/ Subhashis Banerjee at $9.01 per share; the company said these were primarily for tax withholding related to equity vesting, which makes them less alarming than open-market selling. Article Title
• Neutral Sentiment: Recent analyst commentary remains constructive overall, with multiple firms raising price targets sharply, but the stock also faces skepticism from some ratings changes and a still-loss-making earnings profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.95 per share, wider than expectations, reinforcing concerns about ongoing losses and execution risk.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ARTV. Wedbush increased their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Cantor Fitzgerald upped their target price on Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Needham & Company LLC upped their target price on Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Finally, Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.